ArticleHepatology international2008
Hepatitis B reactivation after chemotherapy: two decades of clinical research.
Article in Hepatology international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.Hepatology international · 2021Guideline
- Senior adult oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2012Guideline
- Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.Digestive diseases and sciences · 2021Trial
- Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.Hepatology international · 2015Trial
- Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma.World journal of biological chemistry · 2026Review
- Immunodeficiencies in Adults: Key Considerations for Diagnosis and Management.Clinical reviews in allergy & immunology · 2025Review
- Characterization of occult hepatitis B infection among Iranian liver transplant recipients.Journal of clinical laboratory analysis · 2022Article
- Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.Journal of personalized medicine · 2021Review
- Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma.BMJ case reports · 2021Review
- What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Effect of COVID-19 on patients with compensated chronic liver diseases.Hepatology international · 2020Article
- Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence.JAMA network open · 2020Article
- Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series.Journal of clinical and translational hepatology · 2018Article
- Strategies for prediction and mitigation of radiation-induced liver toxicity.Journal of radiation research · 2018Article
- Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia.International journal of hematology · 2017Article
- Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection.Gastroenterology & hepatology · 2017Article
- Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt.World journal of hepatology · 2017Article
- Effect of Bicyclol Tablets on Drug Induced Liver Injuries after Kidney Transplantation.Open medicine (Warsaw, Poland) · 2017Article
- Review
- Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective.Insights into imaging · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis due to hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy is a serious cause of liver-related morbidity and mortality. With the characterization of the underlying pathogenesis, much progress in the management of this important clinical problem has been made in the past 2 decades. By year 2008, it is mandatory to screen for hepatitis B surface antigen status before initiating intensive chemotherapy or immunosuppressive therapy. All those who are hepatitis B surface antigen positive should be started on preemptive nucleos(t)ide analogues. However, there remains important issues, such as the type and duration of nucleos(t)ide analogue therapy, which need to be understood. As not all hepatitis B surface antigen-positive patients will suffer from HBV reactivation, it is therefore useful to identify risk factors related to HBV reactivation so that patients will not be treated unnecessarily with nucleos(t)ide analogues. To date, a high baseline level of viral replication, as reflected by high serum HBV DNA level, positive serum hepatitis B e antigen, and a high intrahepatic covalently closed circular DNA level, is the most important predictor for HBV reactivation. Recently, there has been an increased awareness of reactivation of occult hepatitis B virus, especially in hepatitis B virus endemic area, such as the Asia-Pacific region. Careful epidemiological study will be needed to clarify the impact of occult hepatitis B infection in patients treated with cytotoxic or immunosuppressive therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.